MedRx Co., Ltd (TYO:4586)
Japan · Delayed Price · Currency is JPY 67.00
+1.00 (1.52%)
Aug 27, 2026, 3:30 PM JST
MedRx Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 7 | 3 | - | 7 | 9 | 8 |
Other Revenue | 114 | 125 | 257 | 22 | 50 | - |
| 121 | 128 | 257 | 29 | 59 | 8 | |
Revenue Growth | 175.00% | -50.20% | 786.21% | -50.85% | 637.50% | -93.04% |
Cost of Revenue | 3 | 2 | - | 3 | 3 | 2 |
Gross Profit | 118 | 126 | 257 | 26 | 56 | 6 |
Selling, General & Admin | 143 | 217 | 203 | 221 | 232 | 270 |
Research & Development | 850 | 850 | 846 | 737 | 921 | 794 |
Operating Expenses | 994 | 1,068 | 1,050 | 960 | 1,157 | 1,067 |
Operating Income | -876 | -942 | -793 | -934 | -1,101 | -1,061 |
Interest Expense | - | - | - | - | - | -1 |
Interest & Investment Income | 4 | 2 | - | - | - | - |
Currency Exchange Gain (Loss) | - | -5 | -1 | 11 | -3 | 1 |
Other Non Operating Income (Expenses) | 5 | 8 | 40 | -7 | -8 | -12 |
EBT Excluding Unusual Items | -867 | -937 | -754 | -930 | -1,112 | -1,073 |
Gain (Loss) on Sale of Investments | - | - | -68 | - | - | - |
Other Unusual Items | 21 | 12 | 20 | - | 2 | 15 |
Pretax Income | -846 | -925 | -802 | -930 | -1,110 | -1,058 |
Income Tax Expense | 13 | 12 | 4 | 2 | 1 | 1 |
Net Income | -859 | -937 | -806 | -932 | -1,111 | -1,059 |
Net Income to Common | -859 | -937 | -806 | -932 | -1,111 | -1,059 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 59 | 54 | 43 | 35 | 25 | 21 |
Shares Outstanding (Diluted) | 59 | 54 | 43 | 35 | 25 | 21 |
Shares Change | 23.04% | 23.62% | 24.99% | 37.12% | 18.76% | 31.47% |
EPS (Basic) | -14.58 | -17.44 | -18.54 | -26.80 | -43.80 | -49.58 |
EPS (Diluted) | -14.58 | -17.44 | -18.54 | -26.80 | -43.80 | -49.58 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -980 | -970 | -803 | -913 | -1,074 | -925 |
Free Cash Flow Per Share | -16.63 | -18.05 | -18.47 | -26.25 | -42.34 | -43.31 |
Gross Margin | 97.52% | 98.44% | 100.00% | 89.66% | 94.92% | 75.00% |
Operating Margin | -723.97% | -735.94% | -308.56% | -3220.69% | -1866.10% | -13262.50% |
Profit Margin | -709.92% | -732.03% | -313.62% | -3213.79% | -1883.05% | -13237.50% |
Free Cash Flow Margin | -809.92% | -757.81% | -312.45% | -3148.28% | -1820.34% | -11562.50% |
EBITDA | -868 | -929 | -755 | -889 | -1,055 | -1,001 |
EBITDA Margin | - | - | -293.77% | - | - | - |
D&A For EBITDA | 8 | 13 | 38 | 45 | 46 | 60 |
EBIT | -876 | -942 | -793 | -934 | -1,101 | -1,061 |